Apyx Medical Corporation announces it has obtained regulatory approval to market and sell its Helium Plasma Technology products in five new countries: Australia, Brazil, Israel, Taiwan and Thailand.
The company’s Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. According to the company in a media release, it has contracted with distributors to market and sell its products in each country.
Related Stories:
- Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion Technology in Dermal Resurfacing Procedures
- Apyx Medical Corporation Receives 510(k) Clearance for the Apyx Plasma/RF Handpiece
“We are very pleased to obtain regulatory approvals to market and sell our Helium Plasma Technology products in these five new countries,” says Charlie Goodwin, the Clearwater, Fla-based company’s president and chief executive officer, in the release.
“We have been focused on pursuing regulatory clearances in international markets as one of our key strategic priorities to enhance Apyx Medical’s long-term growth profile. While we expect each of these new countries to contribute to our growth profile in the coming years, we are especially excited by the growth opportunity we have in Brazil, which is estimated to be the second largest cosmetic surgery market in the world in terms of both the total number of procedures performed and the number of surgeons.
“We shipped an initial commercial order to our distributor in Brazil in late-June and we expect to ship our initial commercial orders to each of the other new countries over the second half of 2020,” he adds.
[Source(s): Apyx Medical Corporation, Business Wire]
